{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NXL104%2Fceftazidime",
    "query": {
      "intervention": "NXL104/ceftazidime"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NXL104%2Fceftazidime&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T01:27:02.102Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01291602",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male and Female Japanese Volunteers"
      ],
      "interventions": [
        {
          "name": "NXL104",
          "type": "DRUG"
        },
        {
          "name": "CAZ104",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "20 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2011-02",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291602"
    },
    {
      "nct_id": "NCT02504827",
      "title": "Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ceftazidime/avibactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-09",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-11-27",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504827"
    },
    {
      "nct_id": "NCT02732327",
      "title": "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "CAZ-AVI",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-05-17",
      "completion_date": "2016-06-27",
      "has_results": true,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02732327"
    },
    {
      "nct_id": "NCT05977868",
      "title": "Comparing Oral Versus Parenteral Antimicrobial Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endovascular Infection",
        "Bone and Joint Infection",
        "Skin and Soft Tissue Infection",
        "Pulmonary Infection",
        "Gastrointestinal Infection",
        "Genitourinary Infection"
      ],
      "interventions": [
        {
          "name": "Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid",
          "type": "DRUG"
        },
        {
          "name": "Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2023-08-04",
      "completion_date": "2025-02-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05977868"
    },
    {
      "nct_id": "NCT04126031",
      "title": "Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gram-negative Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        },
        {
          "name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "88 Days",
        "sex": "ALL",
        "summary": "0 Days to 88 Days"
      },
      "enrollment_count": 48,
      "start_date": "2020-01-14",
      "completion_date": "2022-12-30",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126031"
    },
    {
      "nct_id": "NCT01893346",
      "title": "Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Infections"
      ],
      "interventions": [
        {
          "name": "CAZ-AVI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 35,
      "start_date": "2013-07",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893346"
    },
    {
      "nct_id": "NCT04785924",
      "title": "Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carbapenem-Resistant Enterobacteriaceae Infection",
        "KPC",
        "Gram-Negative Bacterial Infections",
        "Antibiotic Resistant Infection"
      ],
      "interventions": [
        {
          "name": "Imipenem+Relebactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-07",
      "completion_date": "2023-01-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04785924"
    },
    {
      "nct_id": "NCT02475733",
      "title": "Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Intra-abdominal Infections"
      ],
      "interventions": [
        {
          "name": "Ceftazidime -avibactam",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 83,
      "start_date": "2015-08-01",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 4,
      "location_summary": "Orange, California • San Diego, California • Toledo, Ohio + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475733"
    },
    {
      "nct_id": "NCT04358991",
      "title": "Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Ceftazidime-avibactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-01-01",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04358991"
    },
    {
      "nct_id": "NCT01290900",
      "title": "A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male Volunteers"
      ],
      "interventions": [
        {
          "name": "NXL104",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Placebo Infusion",
          "type": "DRUG"
        },
        {
          "name": "Ceftazidime",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 54,
      "start_date": "2011-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-09-22T01:27:02.102Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290900"
    }
  ]
}